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oxidoreductase; NRF2, nuclear factor-erythroid-related factor 2; POR, P450 oxidoreductase; 
RAL, relative adduct labeling; ROS, reactive oxygen species; SDS, sodium dodecyl sulfate; 
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Abstract 
Aristolochic acid causes a specific nephropathy (AAN), Balkan endemic nephropathy, and 
urothelial malignancies. Using Western blotting suitable to determine protein expression, we 
investigated in several transgenic mouse lines expression of NAD(P)H:quinone 
oxidoreductase (NQO1)––the most efficient cytosolic enzyme that reductively activates 
aristolochic acid I (AAI). The mouse tissues used were from previous studies [Arlt et al., 
Chem. Res. Toxicol. 24 (2011) 1710; Stiborova et al., Toxicol. Sci. 125 (2012) 345], in which 
the role of microsomal cytochrome P450 (CYP) enzymes in AAI metabolism in vivo had 
been determined. We found that NQO1 levels in liver, kidney and lung of Cyp1a1(−/−), 
Cyp1a2(−/−) and Cyp1a1/1a2(−/−) knockout mouse lines, as well as in two CYP1A-
humanized mouse lines harboring functional human CYP1A1 and CYP1A2 and lacking the 
mouse Cyp1a1/1a2 orthologs, differed from NQO1 levels in wild-type mice. NQO1 protein 
and enzymic activity were induced in hepatic and renal cytosolic fractions isolated from AAI-
pretreated mice, compared with those in untreated mice. Furthermore, this increase in hepatic 
NQO1 enzyme activity was associated with bioactivation of AAI and elevated AAI-DNA 
adduct levels in ex vivo incubations of cytosolic fractions with DNA and AAI. In conclusion, 
AAI appears to increase its own metabolic activation by inducing NQO1, thereby enhancing 
its own genotoxic potential. 
 
 
Keywords: Aristolochic acid nephropathy; Balkan endemic nephropathy; NAD(P):quinone 
oxidoreductase; Protein expression; Metabolic activation; DNA adducts; Mouse models 
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INTRODUCTION 
 
The herbal drug aristolochic acid (AA) derived from Aristolochia species has been 
shown to be the cause of so-called Chinese herbs nephropathy, now termed aristolochic acid 
nephropathy (AAN) (Debelle et al., 2008; Schmeiser et al., 2009). The plant extract AA is a 
mixture of structurally related nitrophenanthrene carboxylic acids, the major components 
being aristolochic acid I (AAI) and aristolochic acid II (AAII).  
AAN is a rapidly progressive renal fibrosis that was initially observed in a group of 
Belgian women who had ingested weight loss pills containing Aristolochia fangchi 
(Vanherweghem et al., 1993; Nortier et al., 2000). Within a few years of taking the pills, 
AAN patients also showed a high risk (~50%) of upper urothelial tract carcinoma and, 
subsequently, bladder urothelial carcinoma. In the meantime, similar cases have been 
reported elsewhere in Europe and Asia (Schmeiser et al., 2009). Dietary exposure to AA has 
also been linked to Balkan endemic nephropathy (BEN) and its associated urothelial cancer 
(Arlt et al., 2007; Grollman et al., 2007; Moriya et al., 2011); this nephropathy is endemic in 
certain rural areas of Serbia, Bosnia, Croatia, Bulgaria and Romania.  
Exposure to AA was demonstrated by identification of specific AA-DNA adducts in 
urothelial tissue of AAN and BEN patients (Schmeiser et al., 1996; Nortier et al., 2000; Arlt 
et al., 2002; Grollman et al., 2007; Jelakovic et al., 2012; Yun et al., 2012). The most 
abundant DNA adduct detected in patients is 7-(deoxyadenosin-N6-yl)aristolactam I (dA-
AAI) (Fig. 1), which causes characteristic AT→TA transversions. Such AT→TA mutations 
have been observed in the TP53 tumor suppressor gene in tumors from AAN and BEN 
patients (Lord et al., 2004; Grollman et al., 2007; Moriya et al., 2011), indicating a probable 
molecular mechanism associated with AA-induced carcinogenesis (Arlt et al., 2007; Kucab et 
al., 2010). More recently, AA exposure was discovered to contribute to the high incidence of 
upper urinary tract urothelial carcinoma (UUC) in Taiwan, where medicinal use of 
Aristolochia plants is widespread (Chen et al., 2012); again, the TP53 mutational signature in 
patients with UUC was predominant among otherwise rare AT→TA transversions (Olivier et 
al., 2012). AA has been classified as a Group I carcinogen in humans by the International 
Agency for Research on Cancer (Grosse et al., 2009).  
The activation pathway for AAI is nitroreduction, catalyzed by both cytosolic and 
microsomal enzymes; in this process NAD(P)H:quinone oxidoreductase (NQO1) is the most 
efficient cytosolic nitroreductase (Stiborova et al., 2003; Stiborova et al., 2008a; Stiborova et 
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al., 2008b; Chen et al., 2011) (Fig. 1). In contrast to NQO1, conjugation enzymes such as 
human sulfotransferases (SULTs) or N,O-acetyltransferases (NATs) did not significantly 
activate AAI (Martinek et al., 2011; Stiborova et al., 2011). In human hepatic microsomes, 
AAI is activated by cytochrome P450 1A2 (CYP1A2) and, to a lesser extent, by CYP1A1; 
P450 oxidoreductase (POR) also plays a minor role (Stiborova et al., 2001a; Stiborova et al., 
2005). Human and rodent CYP1A1 and 1A2 are also the principal enzymes involved in 
oxidative detoxication of AAI to 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa, 
Fig. 1) (Sistkova et al., 2008; Shibutani et al., 2010).  
The role of cytochrome P450 enzymes, particularly CYP1A1 and CYP1A2, both in 
the reductive activation and oxidative detoxication of AAI, was demonstrated in several 
animal studies. Two studies used the Hepatic P450 Reductase Null (HRN) mice––in which 
the Por gene is deleted specifically in hepatocytes––resulting in absence of CYP activity 
(Xiao et al., 2008; Levova et al., 2011), two others used Cyp1a1(−/−), Cyp1a2(−/−) and/or 
Cyp1a1/1a2(−/−) mouse lines (Rosenquist et al., 2010; Arlt et al., 2011a).  
We also evaluated AAI metabolism mediated by human CYP1A1 and 1A2, 
employing two CYP1A-humanized mouse lines, both carrying functional human CYP1A1 and 
CYP1A2 genes in place of the orthologous mouse genes; one line carries the high-affinity aryl 
hydrocarbon receptor (AHR) [hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1], whereas the other 
line carries the poor-affinity AHR [hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd] (Stiborova et al., 
2012). The latter line is believed to be more relevant to human risk assessment vis-à-vis 
human CYP1A1 and CYP1A2 substrates, because poor-affinity, rather than high-affinity, 
AHR is known to predominate by far in human populations (Nebert et al., 2004). Overall, 
AAI-DNA adduct levels were higher in CYP1A-humanized mice than in wild-type (WT) 
mice, suggesting strongly that human CYP1A1 and 1A2 causes higher AAI bioactivation 
than mouse CYP1A1 and CYP1A2 (Stiborova et al., 2012).  
 Moreover, an exclusive role of human CYP1A1 and 1A2 in AAI oxidation to AAIa 
was observed in human liver microsomes under aerobic (i.e. oxidative) conditions (Stiborova 
et al., 2012). Our results suggest that, in addition to CYP1A1 and 1A2 expression levels, pO2 
levels in specific organs or even cells might affect the balance between AAI nitroreduction 
(bioactivation) and demethylation (detoxication) which, in turn, would influence tissue-
specific toxicity or carcinogenicity. However, reductive activation of AAI in these mouse 
lines may not only be dictated by CYP1A1/1A2 (Arlt et al., 2011a; Stiborova et al., 2012) but 
also by NQO1 expression. Indeed, higher AAI-DNA adduct levels in HRN than in WT mice 
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are not only the result of lack of hepatic AAI demethylation by the CYP-dependent system, 
but also by higher NQO1 activity, which activates AAI (Levova et al., 2011). Expression of 
NQO1 protein in hepatic cytosolic samples of HRN mice was more than 3-fold higher than 
that in WT mice (Levova et al., 2011); this was paralleled by increased NQO1 activity and 
AAI-DNA adduct formation in ex vivo cytosolic incubations with DNA and AAI. 
Collectively, these results suggest that deletion of the Por gene and absence of the POR 
enzyme in liver is partially compensated by increases in expression of the cytosolic 
nitroreductase NQO1 (Levova et al., 2011).  
In the present study, the influence of AAI exposure upon NQO1 protein expression in 
Cyp1a-knockout and CYP1A-humanized mouse lines was studied by Western blot. Hepatic, 
renal and pulmonary cytosolic NQO1 expression in untreated vs AAI-pretreated mice was 
evaluated. NQO1 enzyme activity plus AAI-DNA adduct formation catalyzed by hepatic 
cytosols were also determined. 
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MATERIAL AND METHODS 
Animal experiments. Generation of Cyp1a1(−/−) (Dalton et al., 2000), Cyp1a2(−/−) (Liang et 
al., 1996), and Cyp1a1/1a2(−/−) (Dragin et al., 2007) knockout mouse lines (on a >99.8% 
C57BL/6J background) has been described. Creation of CYP1A-humanized mouse lines––
namely, hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd 
(both on a >99.8% C57BL/6J background––has also been described (Dragin et al., 2007; Shi 
et al., 2008). Age-matched C57BL/6J Cyp1(+/+) WT mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). Groups of female mice (3 months old; 25-30 g; n = 
4/group) were treated with a single dose of AAI as sodium salt in water (50 mg/kg body 
weight) by oral gavage 24 h before sacrifice (Arlt et al., 2011a; Stiborova et al., 2012). All 
experiments were approved by, and conducted in accordance with, the National Institute of 
Health standards for the care and use of experimental animals and the University of 
Cincinnati Medical Center Institutional Animal Care and Use Committee.  
 
Preparation of cytosolic samples. Hepatic, renal and pulmonary cytosolic fractions from 
untreated and AAI-pretreated Cyp1a1(−/−), Cyp1a2(−/−), and Cyp1a1/1a2(−/−) mice (Arlt et 
al., 2011a), CYP1A-humanized (Stiborova et al., 2012) and WT mice (Arlt et al., 2011a; 
Stiborova et al., 2012) were isolated as previously described (Stiborova et al., 2003; Martinek 
et al., 2011; Stiborova et al., 2011). Pooled cytosolic fractions (n = 4 mice/group) were used 
for these analyses.  
 
Determination of NQO1 protein levels by Western blotting. NQO1 antibodies were prepared 
as described previously (Stiborova et al., 2006). Immunoquantification of cytosolic NQO1 
was carried out on proteins transferred to nitrocellulose membranes after separation by 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (Stiborova et al., 2006). 
Human recombinant NQO1 (Sigma) was used to identify the NQO1 band from mouse 
cytosol. Glyceraldehyde phosphate dehydrogenase was used as loading control and detected 
by its antibody (1:750, Millipore; MA, USA). 
 
Measurement of NQO1 enzyme activity. NQO1 activity was determined using menadione as 
substrate as reported, a method improved by the addition of cytochrome c (Mizerovska et al., 
2011).  
 
 7
Cytosolic AAI-DNA adduct formation by 32P-postlabeling. Incubation mixtures, in a final 
volume of 750 µl, included 50 mM Tris-HCl buffer (pH 7.4) containing 0.2% Tween 20, 1 
mM NADPH, 1 mg mouse liver cytosolic protein, 0.5 mg calf thymus DNA (2 mM dNp) and 
0.5 mM AAI (Stiborova et al., 2003). Incubations were carried out at 37°C for 60 min; AAI-
derived DNA adduct formation is known to be linear up to 2 hr (Stiborova et al., 2003). 
Control incubations were carried out (i) without cytosol, (ii) without NADPH, (iii) without 
DNA, or (iv) without AAI. After extraction with ethyl acetate, DNA was isolated from the 
residual water phase by the standard phenol/chloroform extraction method. 32P-Postlabelling 
assay using the nuclease P1 enrichment version, and thin-layer chromatography (TLC) for 
analysis of AAI-DNA adduct formation, were performed as described (Schmeiser et al., 
1996; Bieler et al., 1997). TLC sheets were scanned using a Packard Instant Imager (Dowers 
Grove; USA). DNA adduct levels (RAL, relative adduct labeling) were calculated as 
described (Schmeiser et al., 1996; Stiborova et al., 2003). Results were expressed as DNA 
adducts/108 nucleotides. Because of low protein concentrations in renal and pulmonary 
cytosolic fractions, AAI-DNA adduct formation in these cytosolic samples was not carried 
out.  
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RESULTS  
 
Using the Western blot method, we compared NQO1 protein levels in Cyp1a-
knockout, CYP1A-humanized mouse lines, and WT mice. In addition, the effect of AAI 
treatment was also examined. 
 
NQO1 protein levels and enzyme activity in Cyp1a-knockout mouse lines  
 
NQO1 protein was detected in all cytosolic samples investigated. Statistically significantly 
higher levels of NQO1 expression were found in liver, kidney and lung of untreated 
Cyp1a1(−/−), Cyp1a2(−/−) and Cyp1a1/1a2(−/−) mice, compared with those in WT mice 
(Fig. 2). Higher NQO1 protein levels in liver of all Cyp1a-knock-out mice paralleled higher 
NQO1 enzyme activities (Fig. 2, left panel). However, this was not the case in kidney: NQO1 
enzyme activity was not different among Cyp1a1(−/−), Cyp1a2(−/−) and WT mice and was 
lower in Cyp1a1/1a2(−/−) mice (Fig. 2, middle panel). NQO1 protein levels in lung could not 
be compared with NQO1 enzyme activity, because NQO1 activity was not detectable in 
Cyp1a1(−/−) or Cyp1a1/1a2(−/−) lung cytosol (Fig. 2, right panel)––despite lung NQO1 
protein levels that appeared similar to levels seen in liver. AAI pretreatment induced NQO1 
protein levels not only in WT liver, kidney and lung cytosol but also in Cyp1a1(−/−) liver, 
Cyp1a1(−/−) kidney, Cyp1a2(−/−) kidney, Cyp1a1/1a2(−/−) kidney,  Cyp1a1(−/−) lung, and 
Cyp1a2(−/−) lung (Fig. 2). This increase was associated with enhanced NQO1 enzyme 
activities in liver and kidney cytosolic fractions (Fig. 2, lower panels). No NQO1 enzyme 
activity was detectable in pulmonary cytosol from AAI-pretreated mice.   
 
NQO1 protein levels and enzyme activity in CYP1A-humanized mouse lines 
 
Liver and kidney NQO1 protein levels were significantly higher in both lines of CYP1A-
humanized mice, compared with those in WT mice. In lung cytosol from 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd, lower NQO1 protein levels were found (Fig. 3). 
Overall, NQO1 enzyme activity paralleled protein levels in liver and kidney; however, no 
cytosolic NQO1 activity was detectable in lung of either CYP1A-humanized mouse line (Fig. 
3).  
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AAI pretreatment enhanced cytosolic NQO1 protein levels also in CYP1A-humanized 
mice: 2.6- and 2.3-fold higher, respectively, in liver from 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd, 
compared with that in untreated mice. Also in kidney from 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 mice, 1.4-higher NQO1 protein levels, than in 
untreated mice were found (Fig. 3). 
Increased renal NQO1 protein levels were associated with enhanced NQO1 enzyme 
activity (Fig. 3, middle panel). Cytosolic NQO1 enzyme activity was either the same or lower 
in liver from AAI-pretreated CYP1A-humanized mice than that of untreated mice (Fig. 3, left 
panel).  
More than 2-fold higher NQO1 protein levels were also induced by AAI in lung 
cytosol in hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice relative to those of untreated mice, but no 
cytosolic NQO1 enzyme activity was detectable in the lung of either CYP1A-humanized 
mouse line (Fig. 3, right panel). 
 
AAI-DNA adduct formation mediated by liver cytosol  
 
Hepatic cytosol from AAI-pretreated mice was compared with that from untreated mice 
(Table 1). AAI was metabolically activated in all samples tested, to generate the same pattern 
of AAI-DNA adducts, consisting of three DNA adducts (see Fig. 1, insert) determined by 32P-
postlabeling. This same DNA adduct pattern has been observed in urothelial tissue from 
AAN and BEN patients (Nortier et al., 2000; Arlt et al., 2002). These adducts have previously 
been identified (Schmeiser et al., 1996; Stiborova et al., 2003) as 7-(deoxyadenosin-N6-
yl)aristolactam I (dA-AAI), 7-(deoxyguanosin-N2-yl)aristolactam I (dG-AAI) and 7-
(deoxyadenosin-N6-yl)aristolactam II (dA-AAII) (Fig. 1). No DNA adducts were observed in 
control incubations carried out in parallel without cytosol, or without DNA, or without AAI 
(data not shown).  
Cyp1a1(−/−), Cyp1a2(−/−) and Cyp1a1/1a2(−/−) hepatic cytosol from untreated mice 
led to as much as ~2-fold higher AAI-DNA adduct levels than that from WT mice (Table 1). 
Likewise, hepatic cytosol from untreated hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice 
catalyzed ~2-fold higher AAI-DNA adduct levels than that from WT mice, whereas no 
statistically significantly different adduct levels were seen with 
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hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 cytosol. Higher AAI-DNA adducts were only 
observed with cytosols from these mice after AAI treatment, when all cytosols exhibited 
similar AAI activating potency – irrespective of their genotype (Table 1). These enhanced 
AAI-DNA adduct levels corresponded to higher cytosolic NQO1 enzyme activity (compare 
Figs. 2 & 3).  
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DISCUSSION 
 
Previously we found that AAI, in the presence of NADPH (a cofactor of NQO1), is 
activated by human liver and kidney cytosolic fractions, as well as by purified human NQO1, 
to DNA adducts identical to those found in humans diagnosed with AAN and BEN 
(Stiborova et al., 2003; Martinek et al., 2011; Stiborova et al., 2011). These data suggested 
that NQO1 might be the principle enzyme responsible for AAI activation. In the present 
study, we used Western blotting analysis to determine NQO1 protein levels in cytosol from 
liver, kidney and lung of Cyp1a-knockout mice lacking the CYP1A1 and/or CYP1A2 
enzymes, and in CYP1A-humanized mouse lines expressing human CYP1A1 and 1A2 in 
place of the mouse orthologs. NQO1 enzyme activity and AAI-DNA adduct levels formed in 
in-vitro incubations were also measured. Further, we evaluated not only basal NQO1 
expression, but also NQO1 expression following AAI pretreatment. These data should 
enhance our understanding of the potential role of NQO1 in AAI bioactivation.   
Our results demonstrate that cytosolic NQO1 protein levels and enzyme activity are 
higher in liver and kidney from the three Cyp1a-knockout mouse lines and the CYP1A-
humanized mice; NQO1 activity in lung was not detected, despite measurable protein levels. 
Higher liver cytosolic NQO1 activity resulted in bioactivation and, hence, elevated AAI-
DNA adduct formation, when cytosol was incubated ex vivo with DNA and AAI. The highest 
DNA adduct levels were seen with cytosol from Cyp1a2(−/−) and Cyp1a1/1a2(−/−) as well 
as from hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice. In contrast, only slightly higher AAI-
DNA adduct levels were generated by Cyp1a1(−/−) hepatic cytosol. This finding is consistent 
with a previous study showing that ablation of the Cyp1a1 gene was not sufficient to alter 
hepatic constitutive expression of other genes in the mouse Ahr battery including Nqo1 
(Dalton et al., 2000).  
Our results also indicate that pretreatment with AAI induces NQO1 protein levels and 
enzyme activity in liver and kidney cytosol from these transgenic as well as WT mice. The 
highest increase in NQO1 was found in kidney, followed by lung and liver. These data 
suggest that AAI can induce NQO1 in kidney – which is the target organ of AAI-induced 
toxicity; moreover, AAI induced NQO1 in liver, the most important organ responsible for 
metabolism of xenobiotics including AAI. This is consistent with previous studies where 
NQO1 activity was increased in kidney of rats pretreated with AAI (Stiborova et al., 2001b), 
and NQO1 protein levels were induced by AAI in mouse kidney (Arlt et al., 2011b). Hence, 
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this enzyme is likely to be induced in the kidneys of AAN and BEN patients, which may 
contribute to their increased risk for urothelial cancer. 
Thus far, we can only speculate on the mechanisms responsible for AAI-mediated 
NQO1 induction. NQO1 expression has been shown to be regulated by two distinct 
regulatory elements in the 5’ flanking region of the NQO1 gene, the antioxidant response 
element (ARE) and the xenobiotic response element (XRE), involving ligand-activated AHR 
(Nebert and Jones, 1989; Ross et al., 2000; Jaiswal, 2004; Nioi and Hayes, 2004). In ARE-
mediated NQO1 induction, nuclear factor-erythroid 2-related factor 2 (NRF2) and the 
cytoskeletal-binding protein KEAP1 (Kelch-like ECH-associating protein 1) play an 
important role (i.e. the NRF2-KEAP1 mechanism of NQO1 induction). ARE-mediated 
NQO1 gene expression is increased by a variety of antioxidants, tumor promoters and 
reactive oxygen species (ROS) (Li and Jaiswal, 1994). ROS has been shown to be generated 
in several human cell lines in culture after AAI exposure (Yu et al., 2011; Zhu et al., 2012). 
Hence, an increase in AAI-mediated ROS formation might be one mechanism by which AAI 
induces NQO1. However, the question whether ROS formation during AAI metabolism is the 
means by which NQO1 is induced, or by other mechanisms, remains to be explored in future 
studies. 
The XRE-mediated NQO1 induction is still a matter of debate. The human XRE of 
NQO1 shares significant homology with the human CYP1A1 XRE (Nebert et al., 2000). Both 
NQO1 and CYP1A1 genes can be induced by AHR ligands such as 2,3,7,8-
tetrachlorodibenzo[1,4]dioxine and polycyclic aromatic hydrocarbons (Nebert et al., 2000; 
Ross et al., 2000; Nioi and Hayes, 2004). However, some AHR ligands such as β-
naphthoflavone or certain azo dyes can be metabolized by CYPs to oxidative metabolites that 
can activate ARE-driven gene expression (De Long et al., 1987). Prochaska and Talalay 
(1988) have referred to compounds that can stimulate both XRE- and ARE-driven gene 
expressions as "bi-functional inducing agents". Moreover, cross-talk may occur between 
NRF2 and AHR, but the details of this process remain to be elucidated (Jaiswal, 2004). We 
found that AAI treatment led to an increase in ethoxyresorufin O-deethylation, 
methoxyresorufin O-demethylation and Sudan I oxidation in mice (Arlt et al., 2011a; 
Stiborova et al., 2012), all of which are indicators of the XRE-regulated enzymes CYP1A1 
and 1A2. Thus, AAI-mediated enzyme induction by XRE-regulated pathways should also be 
taken into account. Determining which of the above mentioned two mechanism(s) is(are) 
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responsible for AAI-mediated induction of NQO1 and CYP1A will be one of the major 
challenges for future research. 
Of note, it was reported that polymorphisms in the human NQO1 gene are important 
in AA-induced nephropathy (Toncheva et al., 2004; Toncheva, 2006;). Indeed, the 
NQO1*2/*2 genotype, resulting in very low NQO1 levels of expression, was shown to 
predispose BEN patients to a much higher incidence of urothelial cancer (OR=13.75, 95%CI 
1.17-166.21) (Toncheva et al., 2004; Toncheva, 2006). This finding appears to be opposite to 
what one might expect, given our demonstration herein of the importance of NQO1 in AAI 
activation; however, diminished NQO1 metabolism of AAI could lead to an enhanced body 
burden which might lead to increased risk of tumorigenesis over time. 
The situation in lung is completely different from that in the other two organs 
investigated. Basal and induced NQO1 protein levels in lung, as measured by Western 
blotting was similar to that in liver or kidney, but NQO1 enzyme activity was much lower or 
not detectable in lung, especially following AAI pretreatment. Several reasons for this 
observation are possible: the protein that is expressed is in an inactive form; an inhibitor 
might be present in lung cytosol; menadione is not a good substrate for lung NQO1; or the 
lung NQO1 protein has undergone allosteric effects. Which of these might be most important 
in our experiments is hard to say, but it was noticeable that in all cases the lung NQO1 
enzyme activity was not seen following AAI pretreatment. 
In the present study, increases in NQO1 protein levels in kidney and liver correlated 
with NQO1 enzyme activity in these two organs. In liver cytosol, increases in NQO1 protein 
levels also paralleled elevated levels of AAI-DNA adducts. Presence of the human CYP1A 
orthologs regulated by the poor-affinity AHR led to similar results in NQO1 protein levels 
and enzyme activity as seen in the Cyp1a-knock-out mice. Only the high-affinity-AHR 
humanized line showed NQO1 protein and enzyme activity levels comparable to those seen 
in wild-type mice. Together with previous studies (Arlt et al., 2011a; Levova et al., 2011; 
Stiborova et al., 2012), the results herein indicate that, if hepatic CYP1A expressions were 
missing, leading to less detoxication of AAI by demethylation (as seen in Cyp1a-knockout 
mice), then NQO1 would become the major enzyme, leading to higher AAI-DNA adduct 
formation. In addition, we have shown that AAI pretreatment can induce NQO1 in liver and 
kidney, which results in enhanced reductive AAI bio-activation to form hepatic AAI-DNA 
adducts, thereby enhancing the genotoxic potential of AAI. 
In summary, utilizing Western blot analysis, NQO1 protein levels were analyzed in 
Cyp1a-knock-out and CYP1A-humanized mouse lines. Deletion of both Cyp1a genes in these 
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mouse lines resulted in elevated expression of NQO1 protein in the liver and kidney. 
Likewise, CYP1A-humanized mouse lines displayed higher levels of the NQO1 protein in 
liver and kidney. Our results indicate that AAI has the potential to induce the cytosolic NQO1 
nitroreductase activity in mouse liver and kidney. Our studies with CYP1A-humanized mice – 
and the findings of others (Toncheva, 2006) that certain NQO1 genotypes appear to be 
associated with increased risk of urothelial cancer in BEN patients – underscore the clinical 
importance of NQO1 activity in humans exposed to AAI. It is possible that these findings can 
be extrapolated to other nitro-aromatic carcinogens.  
 
Funding 
Financial support from GACR (grant 303/09/0472 and 305/09/H008) and Charles University 
in Prague (UNCE 204025/2012) is highly acknowledged. Work at King’s College London is 
supported by Cancer Research UK. D.H. Phillips and V.M. Arlt are members of European 
Union Network of Excellence ECNIS2 (Environmental Cancer Risk, Nutrition and Individual 
Susceptibility). D.W. Nebert has been supported by R01 ES ES014403 and the P30 
ES006096 Center grant. 
 
Conflict of interest statement 
None. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15
References 
 
Arlt, V. M., Ferluga, D., Stiborova, M., Pfohl-Leszkowicz, A., Vukelic, M., Ceovic, S., 
Schmeiser, H. H., and Cosyns, J. P. (2002). Is aristolochic acid a risk factor for 
Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer 101, 500-
502. 
Arlt, V. M., Levova, K., Barta, F., Shi, Z., Evans, J. D., Frei, E., Schmeiser, H. H., Nebert, D. 
W., Phillips, D. H., and Stiborova, M. (2011a). Role of P450 1A1 and P450 1A2 in 
bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in 
Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem. Res. Toxicol. 24, 1710-1719. 
Arlt, V. M., Stiborova, M., Henderson, C. J., Thiemann, M., Frei, E., Aimova, D., Singh, R., 
Gamboa da Costa, G., Schmitz, O. J., Farmer, P. B., Wolf, C. R., and Phillips, D. H. 
(2008). Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 
contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 
reductase null mice. Carcinogenesis 29, 656-665. 
Arlt, V. M., Stiborova, M., vom Brocke, J., Simoes, M. L., Lord, G. M., Nortier, J. L., 
Hollstein, M., Phillips, D. H., and Schmeiser, H. H. (2007). Aristolochic acid 
mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-
associated urothelial cancer. Carcinogenesis 28, 2253-2261. 
Arlt, V. M., Zuo, J., Trenz, K., Roufosse, C. A., Lord, G. M., Nortier, J. L., Schmeiser, H. H., 
Hollstein, M., and Phillips, D. H. (2011b). Gene expression changes induced by the 
human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int. J. Cancer 
128, 21-32. 
Bieler, C. A., Stiborova, M., Wiessler, M., Cosyns, J. P., van Ypersele de Strihou, C., and 
Schmeiser, H. H. (1997). 32P-post-labelling analysis of DNA adducts formed by 
aristolochic acid in tissues from patients with Chinese herbs nephropathy. 
Carcinogenesis 18, 1063-1067. 
Chen, C. H., Dickman, K. G., Moriya, M., Zavadil, J., Sidorenko, V. S., Edwards, K. L., 
Gnatenko, D. V., Wu, L., Turesky, R. J., Wu, X. R., Pu, Y. S., and Grollman, A. P. 
(2012). Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. 
Sci. U.S.A. 109, 8241-8246. 
Chen, M., Gong, L., Qi, X., Xing, G., Luan, Y., Wu, Y., Xiao, Y., Yao, J., Li, Y., Xue, X., 
Pan, G., and Ren, J. (2011). Inhibition of renal NQO1 activity by dicoumarol 
suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. 
Toxicol. Sci. 122, 288-296. 
Dalton, T. P., Dieter, M. Z., Matlib, R. S., Childs, N. L., Shertzer, H. G., Genter, M. B., and 
Nebert, D. W. (2000). Targeted knockout of Cyp1a1 gene does not alter hepatic 
constitutive expression of other genes in the mouse [Ah] battery. Biochem.Biophys. 
Res. Comm. 267, 184-189. 
Debelle, F. D., Vanherweghem, J. L., and Nortier, J. L. (2008). Aristolochic acid 
nephropathy: a worldwide problem. Kidney Int. 74, 158-169. 
De Long, M. J., Santamaria, A. B., and Talalay, P. (1987).  Role of cytochrome P1-450 in the 
induction of NAD(P)H:quinone reductase in a murine hepatoma cell line and its 
mutants.  Carcinogenesis. 8, 1549-1553 
Dragin, N., Uno, S., Wang, B., Dalton, T. P., and Nebert, D. W. (2007). Generation of 
'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. Biochem. Biophys. Res. 
Comm. 359, 635-642. 
Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., 
Fernandes, A., Rosenquist, T., Medverec, Z., Jakovina, K., Brdar, B., Slade, N., 
 16
Turesky, R. J., Goodenough, A. K., Rieger, R., Vukelic, M., and Jelakovic, B. (2007). 
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc.  Natl. 
Acad.  Sci. U.S.A. 104, 12129-12134. 
Grosse, Y., Baan, R., Straif, K., Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-
Tallaa, L., Guha, N., Galichet, L., and Cogliano, V. (2009). A review of human 
carcinogens-Part A: pharmaceuticals. Lancet Oncol. 10, 13-14. 
Jaiswal, A. K. (2004). Nrf2 signaling in coordinated activation of antioxidant gene 
expression.  Free Radic. Biol. Med. 36, 1199-1207. 
Jelakovic, B., Karanovic, S., Vukovic-Lela, I., Miller, F., Edwards, K. L., Nikolic, J., Tomic, 
K., Slade, N., Brdar, B., Turesky, R. J., Stipancic, Z., Dittrich, D., Grollman, A. P., 
and Dickman, K. G. (2012). Aristolactam-DNA adducts are a biomarker of 
environmental exposure to aristolochic acid. Kidney Int. 81, 559-567. 
Kucab, J. E., Phillips, D. H., and Arlt, V. M. (2010). Linking environmental carcinogen 
exposure to TP53 mutations in human tumours using the human TP53 knock-in 
(Hupki) mouse model. FEBS J. 277, 2567-2583. 
Levova, K., Moserova, M., Kotrbova, V., Sulc, M., Henderson, C. J., Wolf, C. R., Phillips, D. 
H., Frei, E., Schmeiser, H. H., Mares, J., Arlt, V. M., and Stiborova, M. (2011). Role 
of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic 
aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null 
(HRN) mouse model. Toxicol. Sci. 121, 43-56. 
Li, Y., and Jaiswal, A.K. (1994). Human antioxidant-response-element-mediated regulation 
of type 1 NAD(P)H:quinone oxidoreductase gene expression. Effectof sulfhydryl 
modifying agents.  Eur. J. Biochem. 226, 31-39.  
Liang, H. C., Li, H., McKinnon, R. A., Duffy, J. J., Potter, S. S., Puga, A., and Nebert, D. W. 
(1996). Cyp1a2(-/-) null mutant mice develop normally but show deficient drug 
metabolism. Proc. Natl. Acad. Sci. U.S.A. 93, 1671-1676. 
Lord, G. M., Hollstein, M., Arlt, V. M., Roufosse, C., Pusey, C. D., Cook, T., and Schmeiser, 
H. H. (2004). DNA adducts and p53 mutations in a patient with aristolochic acid-
associated nephropathy. Am J Kidney Dis 43, e11-17. 
Martinek, V., Kubickova, B., Arlt, V. M., Frei, E., Schmeiser, H. H., Hudecek, J., and 
Stiborova, M. (2011). Comparison of activation of aristolochic acid I and II with 
NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro. 
Endocrinol. Lett. 32 Suppl 1, 57-70. 
Mizerovska, J., Dracinska, H., Frei, E., Schmeiser, H. H., Arlt, V. M., and Stiborova, M. 
(2011). Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-
nitrobenzanthrone in liver, kidney and lung, after intra-tracheal instillation in rats. 
Mutat.  Res. 720, 34-41. 
Moriya, M., Slade, N., Brdar, B., Medverec, Z., Tomic, K., Jelakovic, B., Wu, L., Truong, S., 
Fernandes, A., and Grollman, A. P. (2011). TP53 Mutational signature for aristolochic 
acid: an environmental carcinogen. Int. J. Cancer 129, 1532-1536. 
Nebert, D. W., Dalton, T. P., Okey, A. B., and Gonzalez, F. J. (2004). Role of aryl 
hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental 
toxicity and cancer. J. Biol. Chem. 279, 23847-23850. 
Nebert, D. W., and Jones, J. E. (1989). Regulation of the mammalian cytochrome P1-450 
(CYP1A1) gene. Int. J. Biochem. 3, 243-252. 
Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., and Dalton, T.P. (2000). 
Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative 
stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 59, 65-85. 
Nioi, P., and Hayes, J. D. (2004). Contribution of NAD(P)H:quinone oxidoreductase 1 to 
protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region 
 17
leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription 
factors.  Mutat. Res. 555, 149-171. 
Nortier, J. L., Martinez, M. C., Schmeiser, H. H., Arlt, V. M., Bieler, C. A., Petein, M., 
Depierreux, M. F., De Pauw, L., Abramowicz, D., Vereerstraeten, P., and 
Vanherweghem, J. L. (2000). Urothelial carcinoma associated with the use of a 
Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342, 1686-1692. 
Olivier, M., Hollstein, M., Schmeiser, H. H., Straif, K., and Wild, C. P. (2012). Upper urinary 
tract urothelial cancer: where it is A:T. Nat. Rev., xxxxx. 
Prochaska, H. J., and Talalay, P. (1988). Regulatory mechanisms of monofunctional and 
bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res. 48, 4776–
4782. 
Rosenquist, T. A., Einolf, H. J., Dickman, K. G., Wang, L., Smith, A., and Grollman, A. P. 
(2010). Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug 
Metab. Disp. 38, 761-768. 
Ross, D., Kepa, J. K., Winski, S. L., Beall, H. D., Anwar, A., and Siegel, D. (2000). 
NAD(P)H:quinone oxidoreductase (NQO1): chemoprotection, bioactivation, gene 
regulation and genetic polymorphisms. Chem. Biol. Interact. 129, 77-97. 
Schmeiser, H. H., Bieler, C. A., Wiessler, M., van Ypersele de Strihou, C., and Cosyns, J. P. 
(1996). Detection of DNA adducts formed by aristolochic acid in renal tissue from 
patients with Chinese herbs nephropathy. Cancer Res. 56, 2025-2028. 
Schmeiser, H. H., Stiborova, M., and Arlt, V. M. (2009). Chemical and molecular basis of the 
carcinogenicity of Aristolochia plants. Curr. Opin. Drug Dis. Develop. 12, 141-148. 
Shi, Z., Chen, Y., Dong, H., Amos-Kroohs, R. M., and Nebert, D. W. (2008). Generation of a 
'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-
affinity aryl hydrocarbon receptor. Biochem. Biophys. Res. Comm. 376, 775-780. 
Shibutani, S., Bonala, R. R., Rosenquist, T., Rieger, R., Suzuki, N., Johnson, F., Miller, F., 
and Grollman, A. P. (2010). Detoxification of aristolochic acid I by O-demethylation: 
less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer 
127, 1021-1027. 
Sistkova, J., Hudecek, J., Hodek, P., Frei, E., Schmeiser, H. H., and Stiborova, M. (2008). 
Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic 
aristolochic acid. Neuro. Endocrinol. Lett. 29, 733-737. 
Stiborova, M., Dracinska, H., Hajkova, J., Kaderabkova, P., Frei, E., Schmeiser, H. H., 
Soucek, P., Phillips, D. H., and Arlt, V. M. (2006). The environmental pollutant and 
carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are 
potent inducers of rat hepatic cytochromes P450 1A1 and -1A2 and 
NAD(P)H:quinone oxidoreductase. Drug Metab. Disp. 34, 1398-1405. 
Stiborova, M., Frei, E., Arlt, V. M., and Schmeiser, H. H. (2008a). Metabolic activation of 
carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. 
Res. 658, 55-67. 
Stiborova, M., Frei, E., Hodek, P., Wiessler, M., and Schmeiser, H. H. (2005). Human 
hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 
reductase and prostaglandin H synthase mediate the formation of aristolochic acid-
DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113, 189-197. 
Stiborova, M., Frei, E., and Schmeiser, H. H. (2008b). Biotransformation enzymes in 
development of renal injury and urothelial cancer caused by aristolochic acid. Kidney 
Int. 73, 1209-1211. 
Stiborova, M., Frei, E., Sopko, B., Sopkova, K., Markova, V., Lankova, M., Kumstyrova, T., 
Wiessler, M., and Schmeiser, H. H. (2003). Human cytosolic enzymes involved in the 
metabolic activation of carcinogenic aristolochic acid: evidence for reductive 
 18
activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24, 1695-
1703. 
Stiborova, M., Frei, E., Wiessler, M., and Schmeiser, H. H. (2001a). Human enzymes 
involved in the metabolic activation of carcinogenic aristolochic acids: evidence for 
reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 14, 
1128-1137. 
Stiborová, M., Hájek, M., Vošmiková, H., Frei, E., and Schmeiser H.H. (2001b). Isolation of 
DT-diaphorase [NAD(P)H dehydrogenase (quinone)] from rat liver cytosol: 
identification of new substrates, carcinogenic aristolochic acids. Collect. Czech. 
Chem. Comm. 66, 959-972. 
Stiborova, M., Levova, K., Barta, F., Shi, Z., Frei, E., Schmeiser, H. H., Nebert, D. W., 
Phillips, D. H., and Arlt, V. M. (2012). Bioactivation versus detoxication of the 
urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. 
Toxicol. Sci. 125, 345-358. 
Stiborova, M., Mares, J., Frei, E., Arlt, V. M., Martinek, V., and Schmeiser, H. H. (2011). 
The human carcinogen aristolochic acid i is activated to form DNA adducts by human 
NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or 
sulfotransferases. Environ. Mol. Mutagen. 52, 448-459. 
Stiborova, M., Martinek, V., Rydlova, H., Hodek, P., and Frei, E. (2002). Sudan I is a 
potential carcinogen for humans: evidence for its metabolic activation and 
detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. 
Cancer Res. 62, 5678-5684. 
Toncheva, D. I. (2006). Genetic studies in BEN and associated urothelian cancers. Coll. 
Antropol. 30 (Suppl 1), 34. 
Toncheva, D. I., von Ahsen, N., Atanasova, S. Y., Dimitrov, T. G., and Amstrong, V. M. 
(2004). Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients 
with Balkan endemic nephropathy. J. Nephrol. 17, 384-389. 
Vanherweghem, J. L., Depierreux, M., Tielemans, C., Abramowicz, D., Dratwa, M., Jadoul, 
M., Richard, C., Vandervelde, D., Verbeelen, D., Vanhaelen-Fastre, R., and et al. 
(1993). Rapidly progressive interstitial renal fibrosis in young women: association 
with slimming regimen including Chinese herbs. Lancet 341, 387-391. 
Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., Li, L., Liu, L., Qi, X., Zhang, Y., Li, 
Y., Luo, H., Xie, T., Gu, J., and Ren, J. (2008). Hepatic cytochrome P450s metabolize 
aristolochic acid and reduce its kidney toxicity. Kidney Int. 73, 1231-1239. 
Yu, F. Y., Wu, T. S., Chen, T.W., and Liu, B. H. (2011). Aristolochic acid I induced 
oxidative DNA damage associated with glutathione depletion and ERK1/2 activation 
in human cells. Toxicol. In Vitro. 25, 810-816.  
Yun, B. H., Rosenquist, T. A., Sidorenko, V., Iden, C. R., Chen, C. H., Pu, Y. S., Bonala, R., 
Johnson, F., Dickman, K. G., Grollman, A. P., and Turesky, R. J. (2012). 
Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-
performance liquid chromatography/ion-trap mass spectrometry. Chem. Res. Toxicol. 
25, 1119-1131. 
Zhu, S., Wang, Y., Jin, J., Guan, C., Li, M., Xi, C., Ouyang, Z., Chen, M., Qiu, Y., Huang, 
M., and Huang, Z. (2012). Endoplasmic reticulum stress mediates aristolochic acid I-
induced apoptosis in human renal proximal tubular epithelial cells. Toxicol. In Vitro. 
26, 663-671.  
 
 
 19
Table 1. AAI-DNA adduct formation by hepatic cytosol isolated from Cyp1a-knockout, 
CYP1A-humanized and WT mice – untreated versus pretreated for 24 h with AAI (single oral 
dose, 50 mg/kg body weight) 
Mouse line RAL per 108 nucleotides 
  
untreated mice 
mice pretreated with 
50 mg/kg body weight 
AAI 
WT 1.9 ± 0.2 3.4 ± 0.3## 
Cyp1a1(−/−)                                                      2.8 ± 0.3* 3.7 ± 0.4# 
Cyp1a2(−/−)                                                       3.7 ± 0.4** 3.1 ± 0.3 
Cyp1a1/1a2(−/−)   
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1         
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd          
   3.3 ± 0.3** 
2.3 ± 0.2 
    3.9 ± 0.4**                                       
3.6 ± 0.3 
   3.6 ± 0.4## 
3.4 ± 0.3 
Relative adduct labelling (RAL) values are given as means ± S.E.M. (n = 3). * P<0.05, ** 
P<0.01 (different from WT untreated mice); # p<0.05, ## p<0.01 (different from mice with 
the same genetic background not pretreated with AAI. Comparisons were made by Student's 
t-test. 
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Legends to figures 
 
Figure 1  
Pathways of biotransformation and DNA adduct formation of AAI. dA-AAI, 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI, 7-(deoxyguanosin-N2-yl)aristolactam I; 
NQO1, NAD(P)H:quinone oxidoreductase; NR, nitro-reductase. Insert: Autoradiographic 
profile of AAI-DNA adducts formed by incubation of AAI with hepatic cytosol from WT 
mice, using the nuclease P1 enrichment version of the 32P-postlabeling assay. The adduct 
profile shown is representative of those obtained in hepatic cytosolic fractions of other mouse 
lines.  
 
Figure 2  
NQO1 protein levels (black columns) and NQO1 enzyme activity (hatched columns) in 
cytosol isolated from liver, kidney and lung of WT, Cyp1a1(−/−), Cyp1a2(−/−) and 
Cyp1a1/1a2(−/−) mice; animals were either untreated or pretreated with a single AAI oral 
dose (50 mg/kg body weight). Inserts (at top) show Western blots. Cytosol isolated from one 
organ was analyzed in the same blot (e.g. liver untreated versus AAI-pretreated mice) and 
therefore can be directly compared. Human recombinant NQO1 (Sigma) was used to identify 
the mouse NQO1 band in mouse cytosol (data not shown). All values are given as means ± 
S.E.M. (n = 3). Values significantly different from WT mice: *p<0.05, **p<0.01 and 
***p<0.001 (Student’s t-test). 
 
Figure 3  
Cytosolic NQO1 protein levels (black columns) and NQO1 enzyme activities (hatched 
columns) in liver, kidney and lung of WT, hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrb1 and 
hCYP1A1_1A2_Cyp1a1/1a2(−/−)_Ahrd mice; animals were either untreated or pretreated 
with oral AAI (50 mg/kg body weight). All values are given as means ± S.E.M. (n = 3). 
Values significantly different from WT mice: *p<0.05, **p<0.01 and ***p<0.001 (Student’s 
t-test). 
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Figure 3 
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